Pharvaris BV (NASDAQ: PHVS) — Company Overview, News & Financial Data
Pharvaris develops therapies for hereditary angioedema, aiming to provide rapid relief through innovative treatments.
Pharvaris BV
Pharvaris (NASDAQ:PHVS) is a biopharmaceutical company focused on developing innovative therapies for rare diseases, with a particular emphasis on hereditary angioedema (HAE), a disorder characterized by recurrent swelling attacks. Their project pipeline includes novel, small-molecule bradykinin B2 receptor antagonists, designed to provide rapid and reliable relief for HAE sufferers. Pharvaris aims to advance the treatment landscape of HAE by harnessing cutting-edge technology and drug development strategies, striving to improve patient outcomes and quality of life. Their objectives are centered on pushing the boundaries of scientific research to deliver breakthrough solutions that address unmet medical needs within the rare disease community.
Snapshot
Operations
Products and/or services of Pharvaris BV
- Development of oral small molecules for the treatment of hereditary angioedema, a rare genetic disorder causing severe swelling.
- Research into novel mechanisms of action for bradykinin B2 receptor antagonists to address acute and prophylactic care in angioedema conditions.
- Expansion of the portfolio to include therapies for additional bradykinin-mediated diseases, leveraging their expertise in angioedema.
- Collaboration with other pharmaceutical companies for the co-development of innovative treatments for rare diseases.
- Engagement in clinical trials to confirm the efficacy and safety of their lead compounds in treating target conditions.
- Investment in advanced drug delivery technologies to improve patient experience and outcomes in taking their medications.
Pharvaris BV executive team
- Berndt Axel Edvard ModigCo-Founder, CEO & Executive Director
- Peng LuPresident
- David W. NassifCFO, Chief Legal Officer & Corporate Secretary
- Anna NijdamHead of Strategic Finance & Principal Accounting Officer
- Stefan AbeleChief Technology Operations Officer
- Annick DeschoolmeesterChief Human Resources Officer
- Anne A. LesageChief Early Development Officer
- Wim SouverijnsChief Commercial Officer
- Maggie BellerVP & Head of Corporate and Investor Communications
- Maryann CiminoDirector of Corporate Relations
Latest news about Pharvaris BV
Pharvaris reports 83% HAE attack reduction in latest trial results
United StatesPharvaris cash reaches €318 million in Q2
United StatesPharvaris receives regulatory acceptance for drug application
United StatesPharvaris prepares for first FDA submission following success in HAE trials
United StatesPharvaris publishes positive Phase 2 deucrictibant data in the lancet haematology
United StatesPharvaris shares "injectable-like" results for oral HAE drug at AAAAI 2026
United States
Key financials
Reported results for Pharvaris BV, in EUR.
- Market cap
- 2.4B
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -169.8M | -175.7M | |
| 0 | -145.7M | -134.2M | |
| 0 | -96.9M | -100.9M | |
| 0 | -86.7M | -76.3M |